☆ 4.7 Article

Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform

SCIENTIFIC REPORTS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

Robert Roskoski

Summary: Due to the dysregulation of protein kinase activity, this enzyme family has become one of the most important drug targets in the 21st century. There are 68 FDA-approved therapeutic agents that target protein kinases, with six new drugs approved in 2021. These drugs are mainly used in the treatment of neoplasms and inflammatory diseases, with 58 drugs prescribed for tumor treatment. In addition, 18 drugs are used for the treatment of multiple diseases. This review summarizes the physicochemical properties of all FDA-approved small molecule protein kinase inhibitors.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors

Andreas S. Kalogirou et al.

Summary: A focused series of substituted 4H-1,2,6-thiadiazin-4-ones was designed and synthesized to probe the anti-cancer properties of this scaffold. Several low single digit micro molar compounds with promising therapeutic windows, particularly for bladder and prostate cancer, were identified, indicating potential for future improvement. The study also discussed key structural features of the scaffold that show promising scope for further development.

MOLECULES (2021)

添加到收藏夹

Article Chemistry, Medicinal

Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents

Kaitlyn A. Maffuid et al.

Summary: This study explored the potential application of heteroatom-rich 1,2,3-dithiazoles in cancer therapy, identifying several compounds with promising therapeutic effects on breast, bladder, and prostate cancer, and discussing key structural features for potential future refinement.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Trends in kinase drug discovery: targets, indications and inhibitor design

Misty M. Attwood et al.

Summary: The article analyzes the landscape of approved and investigational therapies that target kinases, highlighting the increasing importance of kinase inhibitors in oncology and beyond. It discusses trends in kinase inhibitor design and points out that there are still substantial unexplored opportunities for this drug class.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Acute cell stress screen with supervised machine learning predicts cytotoxicity of excipients

Andrew A. Bieberich et al.

Summary: Excipients act as carriers, preservatives, solubilizers, and colorants for drugs, food, and cosmetics, with some potentially causing adverse effects at biological targets. Compounds were classified into high risk and low risk groups, with the high risk group including known problematic compounds. In vitro assays confirmed the biological activity of compounds in the high risk group.

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships

Christopher R. M. Asquith et al.

CHEMMEDCHEM (2020)

添加到收藏夹

Article Chemistry, Medicinal

Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors

Christopher R. M. Asquith et al.

CHEMMEDCHEM (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Toward in vivo relevant drug design

Robert A. Pearlstein et al.

DRUG DISCOVERY TODAY (2020)

添加到收藏夹

Article Chemistry, Medicinal

SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)

Christopher R. M. Asquith et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK)

Christopher R. M. Asquith et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)

添加到收藏夹

Article Chemistry, Medicinal

Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma

Christopher R. M. Asquith et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines

Christopher R. M. Asquith et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)

添加到收藏夹

Article Chemistry, Medicinal

Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma

Christopher R. M. Asquith et al.

CHEMMEDCHEM (2019)

添加到收藏夹

News Item Biotechnology & Applied Microbiology

ADCK3/COQ8A: the choice target of the UbiB protein kinase-like family

Christopher R. M. Asquith et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK)

Christopher R. M. Asquith et al.

MOLECULES (2019)

添加到收藏夹

Article Oncology

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

J. Ferlay et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury

Paola Magnaghi et al.

MOLECULAR CANCER THERAPEUTICS (2018)

添加到收藏夹

Article Chemistry, Medicinal

Identification and Optimization of 4-Anilinoquinolines as Inhibitors of CyclinG Associated Kinase

Christopher R. M. Asquith et al.

CHEMMEDCHEM (2018)

添加到收藏夹

Article Multidisciplinary Sciences

The target landscape of clinical kinase drugs

Susan Klaeger et al.

SCIENCE (2017)

添加到收藏夹

Article Chemistry, Physical

OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins

Edward Harder et al.

JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)

添加到收藏夹

Article Oncology

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Valentine M. Macaulay et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen

Susanne Scheipl et al.

JOURNAL OF PATHOLOGY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

The promise and peril of chemical probes

Cheryl H. Arrowsmith et al.

NATURE CHEMICAL BIOLOGY (2015)

添加到收藏夹

Review Clinical Neurology

Chordomas: A Review

Bernard George et al.

NEUROSURGERY CLINICS OF NORTH AMERICA (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft

I-Mei Siu et al.

PLOS ONE (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

Theonie Anastassiadis et al.

NATURE BIOTECHNOLOGY (2011)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Comprehensive analysis of kinase inhibitor selectivity

Mindy I. Davis et al.

NATURE BIOTECHNOLOGY (2011)

添加到收藏夹

Article Oncology

Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients

Virginia Ferraresi et al.

BMC CANCER (2010)

添加到收藏夹

Article Chemistry, Physical

Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field

Devleena Shivakumar et al.

JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2010)

添加到收藏夹

Review Oncology

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

Deric L. Wheeler et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Chemistry, Multidisciplinary

Role of the active-site solvent in the thermodynamics of factor Xa ligand binding

Robert Abel et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)

添加到收藏夹

Article Oncology

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647

Steven B. Gendreau et al.

CLINICAL CANCER RESEARCH (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding

Tom Young et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A small molecule-kinase interaction map for clinical kinase inhibitors

MA Fabian et al.

NATURE BIOTECHNOLOGY (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

J Stamos et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.